MYCN Amplification and International Neuroblastoma Risk Grouping [INRG]
A total of 46 cases were evaluated after excluding 4 cases (due to technical reasons); 48% (22/46) cases showed MYCN  amplification and 52% (24/46) showed no amplification.
INRG risk stratification of the cohort was performed by combining age, stage, histologic category/grade, ploidy, and MYCN status. Majority were in the high-risk group (n=36, 60%) followed by intermediate-risk group (n=13, 22%) and low-risk group (n=11, 18%) respectively.